# Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00735930** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Anemia
- Chronic Lymphocytic Leukemia
- Prolymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Thrombocytopenia

## Interventions

- **DRUG:** Alvocidib Hydrochloride
- **DRUG:** Lenalidomide
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00735930
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-03
- **Final completion:** 2014-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735930, "Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00735930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*